These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11366113)

  • 1. Absence makes the HAART grow fonder.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):1-4. PubMed ID: 11366113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. It's the immune system, stupid.
    STEP Perspect; 1999; 99(1):5. PubMed ID: 11367162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
    Levin J
    AIDS Treat News; 1999 May; (No 318):3-4. PubMed ID: 11366456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
    Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
    J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of proviral HIV-1 184M/V in circulating CD4+ T-cells: a 90 days follow-up study after initiation/switch of HAART.
    Mohey R; Katzenstein TL; Black FT; Kjems J; Obel N
    Scand J Infect Dis; 2006; 38(2):119-23. PubMed ID: 16449003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cd4+ T cells programmed to traffic to lymph nodes account for increases in numbers of cd4+ T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection.
    Hengel RL; Jones BM; Kennedy MS; Hubbard MR; McDougal JS
    J Infect Dis; 2001 Jul; 184(1):93-7. PubMed ID: 11398115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.